IWWM-12 live congress feed

Stay up to date with the latest developments in Waldenström's macroglobulinemia from the IWWM-12 with our live social media coverage.

CONGRESS | #IWWM12 | Mazyar Shadman @mshadman @fredhutch shares data from the first patients treated in a phase I/II study of a CD20 CAR T-cell therapy in high-risk B-NHLs including WM. Initial data are promising with the study ongoing.#IWWM2024 #lymsm… pic.twitter.com/39i9lwb74x

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Jeffrey Matous @MileHighMyeloma shares the rationale and design of the ongoing phase II study of sonrotoclax with or without zanubrutinib for R/R and ND WM. The primary endpoint is major response rate by IRC in cohort 1 and is currently enrolling.#IWWM2024… pic.twitter.com/JXH1hmoG5a

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Shuhua Yi shares data from a phase II study of the ZBR regimen in newly diagnosed WM. The ORR rate was 100% and 75% ≥VGPR after maintenance, 66.7% MRD negativity with no cases of IgM rebound after stopping treatment.#IWWM2024 #lymsm… pic.twitter.com/gY2NgSB6CG

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Rebecca Auer @auer_rebecca discusses the ongoing Rainbow trial of ibrutinib-rituximab versus DRC for the treatment of newly diagnosed WM. The primary endpoint is PFS, and aims for a 24-week response rate of 80% with RI. No serious safety signals have been… pic.twitter.com/TcROLH9GGO

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Meletios Dimopoulos shares the background and design of the ongoing CZAR-1 trial of carfilzomib with and without ibrutinib in frontline and R/R WM. Initial safety data includes an overall AE Grade ≥3 rate of 54.4%, 64.4% in arm A, and 44.4% in arm B.… pic.twitter.com/xw8Nl7c8mH

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Shirley D’Sa @ShirleyDSa1 discusses why TP53 mutations may not be appropriate for use in determining treatment decisions in WM currently, concluding that there aren’t enough data for TP53 to guide treatment decisions and for now it is best used as a… pic.twitter.com/cGJ1t33BPZ

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | @LiaPalomba @MSKCancerCenter debates for pirtobrutinib as the next best treatment for patients with WM, progressing on covalent BTK-inhibitors. The debate concludes with a look to combination therapies using pirtobrutinib and venetoclax to improve PFS.… pic.twitter.com/uNgUyL3nci

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Anne-Marie Becking presents the latest data from the retrospective ZaBiNES study, concluding that zanubrutinib may have potential as an effective and tolerable treatment option for patients with Bing Neel syndrome.#IWWM2024 #lymsm…

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Stathis Kastritis @StathisKastr debates for DRC as the standard-frontline therapy for WM. Kastritis emphasises the low rates of toxicity associated with the regimen as well as high response rates, and 4-year treatment-free interval.#IWWM2024 #lymsm… pic.twitter.com/n5pUhoaTgL

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Neil Berinstein debates for limited duration combination therapies with BTKi in the frontline use for WM as the optimal approach. Comparable PFS has been observed with fixed and continuous administration, however less resistant drug variants are observed with… pic.twitter.com/qnIpCOF08R

— Lymphoma Hub (@lymphomahub) October 19, 2024

CONGRESS | #IWWM12 | Adrian Wiestner delivers a keynote lecture on the role of BTKi as facilitators of cellular immunotherapies. BTKi enhance the activity of T-cell engaging bsAbs, indicating a preclinical rationale for combining BTKis with bsAbs, while reducing cytokine release.… pic.twitter.com/eNt9B5MwtK

— Lymphoma Hub (@lymphomahub) October 18, 2024

CONGRESS | #IWWM12 | Charalampia Kyriakou shares the real-world outcomes of ASCT in WM.
The NRM rate at 2- and 5-years is 3% and 4.5%, OS was consistent at 84.1% and 70.4% at 2- and 5-years. Delayed HSCT is associated with inferior PFS and relapse.#IWWM2024 #lymsm… pic.twitter.com/Wlc2RgKCBr

— Lymphoma Hub (@lymphomahub) October 19, 2024